沙利度胺治疗放射性血脑屏障损伤的2期研究
这项西蒙最小最大两阶段、单臂2期临床试验(NCT03208413)评估沙利度胺对 bevacizumab 和糖皮质激素治疗无效或有禁忌的放射性脑损伤患者的疗效。主要终点达到:58例中27例(46.6%,95%CI 33.3至60.1%)治疗后FLAIR-MRI上脑水肿体积缩小≥25%。25例(43.1%)LENT/SOMA量表临床改善,36例(62.1%)MoCA认知改善;小鼠模型显示沙利度胺通过上调PDGFRβ表达功能性挽救周细胞,恢复血脑屏障和脑灌注。
要点
- 58例中27例(46.6%,95%CI 33.3至60.1%)脑水肿体积缩小≥25%,达到主要终点。
- 25例(43.1%)LENT/SOMA量表临床改善,36例(62.1%)MoCA认知改善。
- 小鼠模型显示沙利度胺上调PDGFRβ表达、功能性挽救周细胞,恢复血脑屏障和脑灌注。
核心结论
- 数据表明沙利度胺对放射性脑血管损伤具有治疗潜力。
研究设计与样本
- 西蒙最小最大两阶段、单臂2期临床试验(NCT03208413),纳入对bevacizumab和糖皮质激素治疗无效或有禁忌的放射性脑损伤患者,共58例入组。
主要发现
- 58例中27例治疗后FLAIR-MRI上脑水肿体积缩小≥25%(总体缓解率46.6%,95%CI 33.3至60.1%)。
- 25例(43.1%)基于LENT/SOMA量表显示临床改善。
- 36例(62.1%)基于MoCA评分显示认知改善。
- 小鼠放射性脑损伤模型中,沙利度胺恢复血脑屏障和脑灌注,归因于沙利度胺上调PDGFRβ表达后对周细胞的功能性挽救。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a Simon's minmax two-stage, single-arm, phase 2 clinical trial (NCT03208413) to assess the efficacy of thalidomide in patients with RIBI who were unresponsive to or had contraindications to bevacizumab and corticosteroid therapies. The trial met its primary endpoint, with 27 of 58 patients enrolled showing ≥25% reduction in the volume of cerebral edema on fluid-attenuated inversion recovery-magnetic resonance imaging (FLAIR-MRI) after treatment (overall response rate, 46.6%; 95% CI, 33.3 to 60.1%). Twenty-five (43.1%) patients demonstrated a clinical improvement based on the Late Effects Normal Tissues-Subjective, Objective, Management, Analytic (LENT/SOMA) scale, and 36 (62.1%) experienced cognitive improvement based on the Montreal Cognitive Assessment (MoCA) scores. In a mouse model of RIBI, thalidomide restored the blood-brain barrier and cerebral perfusion, which were attributed to the functional rescue of pericytes secondary to elevation of platelet-derived growth factor receptor β (PDGFRβ) expression by thalidomide. Our data thus demonstrate the therapeutic potential of thalidomide for the treatment of radiation-induced cerebral vasculature impairment.
引用
- Cheng J, Jiang J, He B, et al. A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury. Sci Transl Med. 2023. PMID: 36812346. doi:10.1126/scitranslmed.abm6543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。